MDxHealth SA (NASDAQ:MDXH) Position Trimmed by Bleichroeder LP

Bleichroeder LP decreased its position in MDxHealth SA (NASDAQ:MDXH - Free Report) by 11.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 7,378,333 shares of the company's stock after selling 1,000,000 shares during the period. MDxHealth comprises approximately 4.4% of Bleichroeder LP's portfolio, making the stock its 6th biggest holding. Bleichroeder LP owned about 15.60% of MDxHealth worth $17,487,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Oppenheimer & Co. Inc. lifted its position in MDxHealth by 100.0% in the 4th quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company's stock valued at $47,000 after acquiring an additional 10,000 shares in the last quarter. Perkins Capital Management Inc. raised its stake in MDxHealth by 31.6% during the 4th quarter. Perkins Capital Management Inc. now owns 983,475 shares of the company's stock valued at $2,331,000 after purchasing an additional 236,100 shares during the period. Geode Capital Management LLC purchased a new position in shares of MDxHealth in the fourth quarter worth $25,000. Samjo Management LLC lifted its stake in MDxHealth by 130.9% in the 4th quarter. Samjo Management LLC now owns 1,824,312 shares of the company's stock worth $4,324,000 after purchasing an additional 1,034,312 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of MDxHealth by 715.2% during the 4th quarter. Renaissance Technologies LLC now owns 123,100 shares of the company's stock worth $292,000 after acquiring an additional 108,000 shares in the last quarter.

MDxHealth Price Performance

Shares of NASDAQ:MDXH remained flat at $1.70 during trading on Wednesday. The stock had a trading volume of 67,291 shares, compared to its average volume of 82,650. The stock has a 50 day moving average price of $1.57 and a two-hundred day moving average price of $1.86. MDxHealth SA has a 1-year low of $1.35 and a 1-year high of $3.50. The company has a market cap of $80.39 million, a PE ratio of -1.12 and a beta of 1.32. The company has a debt-to-equity ratio of 3.14, a quick ratio of 1.45 and a current ratio of 1.54.

MDxHealth (NASDAQ:MDXH - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. The company had revenue of $24.74 million during the quarter, compared to analysts' expectations of $22.67 million. On average, equities research analysts anticipate that MDxHealth SA will post -1.15 earnings per share for the current year.

MDxHealth Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.